# Moderna Type: Company (MRNA) Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/moderna Canonical HTML page: https://getbiobrief.com/entity/moderna ## Timeline - **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision. - **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine. - **2026-08-05**: FDA Decision Deadline — The agency faces a deadline to approve or reject the vaccine. - **2026-08-05**: FDA Approval of mRNA-1010 — The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+. - **2026-06**: Advisory Panel Recommends Approval — An FDA advisory panel votes in favor of approving the vaccine. - **2026-03-16**: Court Ruling — Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul. - **2026-03**: Settlement Reached — Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims. - **2026-03-01**: Legal Challenge — The AAP and ACP file suit in Massachusetts federal court to block the changes. - **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute. - **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns. - **2026-02-10**: Political Controversy — Reports emerge that the vaccine chief overruled career scientists to block the shot. - **2026-02**: FDA Issues Refuse-to-File Letter — FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances. - **2026-02**: FDA Accepts Application After Outcry — A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study. - **2026-01-10**: Refusal to File — FDA issues a shocking rejection of the application, sparking a public dispute. - **2026-01**: Refusal to File — FDA issues an RTF citing deficiencies in the initial application. ## Recent coverage (12 stories) ### Moderna Leads 2 MarketBeat Watchlists Among 5 Value Stocks 2026-08-19 21:41:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts. Full story: https://getbiobrief.com/story/moderna-marketbeat-value-bio-aug-2026 ### Moderna's mRNA-1010 Approved with 27.4% Efficacy Lead in 65+ Population 2026-08-06 21:00:31 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2 Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza. Full story: https://getbiobrief.com/story/moderna-mrna-1010-fda-approval-27-4-percent-efficacy ### Moderna’s mFLUSIVA mRNA Flu Vaccine Wins FDA Nod: 40,000-Patient Trial Suggests Superiority 2026-08-06 20:24:09 · Sentiment: Positive · Impact: 6/10 · Sources: 3 The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market. Full story: https://getbiobrief.com/story/moderna-mrna-flu-vaccine-approval-fda ### Moderna's mRNA Flu Shot: FDA Decision by Aug 5 Could End 6-Month Regulatory Ordeal 2026-08-01 15:39:40 · Sentiment: Neutral · Impact: 6/10 · Sources: 6 After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification. Full story: https://getbiobrief.com/story/moderna-mrna-flu-shot-fda-decision-aug-5 ### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026 2026-07-07 06:57:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside. Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome ### Federal Judge Halts RFK Jr.’s Sweeping Vaccine Policy Overhaul 2026-03-17 00:32:23 · Sentiment: Neutral · Impact: 8/10 · Sources: 2 A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws. Full story: https://getbiobrief.com/story/judge-blocks-rfk-jr-vaccine-overhaul ### CDC Data Reveals Suboptimal Flu Vaccine Efficacy for 2025-2026 Season 2026-03-14 23:48:17 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies. Full story: https://getbiobrief.com/story/flu-vaccine-efficacy-decline-us-officials ### Egg Prices Plunge as Avian Flu Recedes, Shifting Focus to Vaccine R&D 2026-03-14 17:01:49 · Sentiment: Positive · Impact: 6/10 · Sources: 2 Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness. Full story: https://getbiobrief.com/story/egg-prices-avian-flu-biotech-impact ### Moderna Leads Biotech Rally as Market Sentiment Shifts Toward Growth 2026-03-04 22:18:29 · Sentiment: Positive · Impact: 6/10 · Sources: 5 Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility. Full story: https://getbiobrief.com/story/moderna-growth-stock-rally-march-2026 ### Moderna to Pay Roivant $2.25 Billion to Settle mRNA Patent Litigation 2026-03-04 14:38:59 · Sentiment: Neutral · Impact: 7/10 · Sources: 2 Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline. Full story: https://getbiobrief.com/story/moderna-roivant-mrna-patent-settlement ### FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine 2026-02-19 00:58:25 · Sentiment: Positive · Impact: 7/10 · Sources: 2 The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy. Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-vaccine-review ### FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute 2026-02-18 18:51:48 · Sentiment: Positive · Impact: 8/10 · Sources: 6 Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application. Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-shot-review --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.